fda label semaglutide naion warning 2025 The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added fda label semaglutide naion warning

Betriebswirtschaft eine Alltagsbersetzung

These findings were shared at a major medical conference (EASD) in September 2025

The MHRA has not authorised it for human use, and it may only be used under specific research conditions

Concerns over treatment cost were also highlighted by T2DXX, as choice of treatment may be made based on affordability for the patient in addition to what is most effective

Natural strategies may not replicate the pharmacological intensity of GLP-1 receptor agonist drugs, but they strengthen endogenous GLP-1 physiology, improve metabolic flexibility, and support sustainable weight loss without dependency or long-term adverse effects